Biotherapeutics Cell Line Development Market (Process: Transfection & Selection and Single Cell Cloning; and CLD Option: In-house, Outsourced, Do-It-Yourself, and Hybrid) - Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Biotherapeutics Cell Line Development market size is expected to hit around USD 415 million by 2030 from valued at USD 210 million in 2021 and growing at a CAGR of 10.4% from 2022 to 2030.

The protein pharmaceutical space has gradually matured into a multibillion-dollar industry over the past couple of decades. However, identifying the ideal bio-therapeutic development cell lines has posed as a major barrier in the manufacturing process. Biotherapeutic cell line development has reached new frontiers, owing to considerable genomic research and development activities. In addition, existing as well as emerging technologies in the biotherapeutics cell line development have played an integral role in pushing cell engineering toward new frontiers. Over the past couple of decades, considerable work has been put in toward optimization of codons and construction of vectors due to which, biotherapeutics cell line development has garnered noteworthy attention.

Regulatory changes, introduction of new technologies, and advent of an array of innovative concepts have played a key role in influencing the overall growth of the global biotherapeutics cell line development market over the past few years– a trend that is expected to continue during the forecast period. Over the past few decades, academic and commercial scientists have largely focused on addressing the shortcomings of initial formulations of biotherapeutics cell lines. Several companies operating in the current biotherapeutics cell line development market landscape are introducing new variants of cell line development solutions to cater to industrial requirements.

Report Scope of the Biotherapeutics Cell Line Development Market

The protein pharmaceutical space has gradually matured into a multibillion-dollar industry over the past couple of decades. However, identifying the ideal bio-therapeutic development cell lines has posed as a major barrier in the manufacturing process. Biotherapeutic cell line development has reached new frontiers, owing to considerable genomic research and development activities. In addition, existing as well as emerging technologies in the biotherapeutics cell line development have played an integral role in pushing cell engineering toward new frontiers. Over the past couple of decades, considerable work has been put in toward optimization of codons and construction of vectors due to which, biotherapeutics cell line development has garnered noteworthy attention.

Regulatory changes, introduction of new technologies, and advent of an array of innovative concepts have played a key role in influencing the overall growth of the global biotherapeutics cell line development market over the past few years– a trend that is expected to continue during the forecast period. Over the past few decades, academic and commercial scientists have largely focused on addressing the shortcomings of initial formulations of biotherapeutics cell lines. Several companies operating in the current biotherapeutics cell line development market landscape are introducing new variants of cell line development solutions to cater to industrial requirements.

 CHO Cells Likely to Remain Integral for Biological Therapeutics

As the protein pharmaceutical industry continues to take giant strides in the forward direction, it has a direct impact on the growth of the biotherapeutics cell line development market. For the longest time, Chinese Hamster Ovary (CHO) cells have remained the most popular expression system for biotherapeutics cell line development, as it is accepted by the FDA and thereby, makes the regulatory approval an easy process. In addition, these biotherapeutics cell lines have the ability to grow in suspension, resistant to viral infection, and are relatively easier to work with. These factors are expected to play a key role in the progress of the global biotherapeutics cell line development market during the assessment period.

However, at present, market players are increasingly focusing on streamlining the process of segregating high-producing protein secretors from low-producing protein secretors, which are highly tedious and time-consuming as over thousands of clones are screened in a period of few weeks. However, the onset of the multi-open reading frame (ORF) constructs in cells could possibly lead to a compromise, fragmented DNA being integrated into the genome in place of the requisite sequence. Market players operating in the current market for biotherapeutics cell line development are increasingly focusing on streamlining segregation processes to fast-track cell line development. At present, the pursuit of novel biopharmaceutical agents continues to remain one of the most critical challenges in the pharmaceutical research and drug development sphere.

Biotherapeutic cell line development plays a critical role in these research activities. However, at present, researchers and scientists are largely focusing on addressing the numerous challenges involved with cell lines such as quality, robustness, productivity, scaling-up, etc.

Mergers, Collaboration, and Entry of New Solutions Provide Impetus for Market Growth

Over the past decade, a number of organizations involved in the biotherapeutics cell line development market are highly inclined toward the development of new technologies that enable the production and manufacturing of various innovative biopharmaceuticals, including gene therapy vectors and complex therapeutic cell lines. In addition, several market participants are also roping in considerable efforts to fast-track screening and biotherapeutics cell line development to develop high-end biopharmaceutical solutions, including complex fusion proteins, viral particles, and largely glycosylated plasma proteins.

Several market players are launching new workflow models to optimize the identification process of top clones for complex antibody therapeutics. For instance, in March 2020, Berkeley Light launched the cell line development 2.0 workflow to identify the most ideal clones for complex antibody therapeutics. The newly launched Opto CLD 2.0 workflow allows the measurement of antibody production in over thousands of clones by utilizing the company’s assays. With a similar aim to increase lab productivity and minimize the timeline of biotherapeutics cell line development, in June 2019, Sartorius Stedim Biotech launched a new generation cell culture micro-bioreactor system.

Market Segmentation: Global Biotherapeutics Cell Line Development Market

• Based on process, the global biotherapeutics cell line development market has been bifurcated into transfection & selection and single cell cloning
• The single cell cloning segment has been sub-divided into manual LDC, FACs, ClonePix, and others
• In terms of CLD option, the global biotherapeutics cell line development market has been divided into in-house, outsourced, Do-It-Yourself, and hybrid
• Each of the segments of the global biotherapeutics cell line development market has been analyzed in detail for recent trends and developments, drivers, restraints, opportunities, and useful insights. The report on the global biotherapeutics cell line development market provides current and future revenues (US$ Mn) for each of these segments for the period from 2017 to 2030, considering 2019 as the base year. The compounded annual growth rate (% CAGR) has been provided for each segment of the market from 2022 to 2030, along with market size estimations.

Regional Overview: Biotherapeutics Cell Line Development Market

• In terms of region, the global biotherapeutics cell line development market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The markets in these regions have been further divided into major countries and sub-regions.
• North America dominated the global biotherapeutics cell line development market in 2019 and the trend is expected to continue during the forecast period
• Asia Pacific is likely to be a highly lucrative market for biotherapeutics cell line development during the forecast period
• The biotherapeutics cell line development market size in terms of revenue (US$ Mn) for different regions and their major countries have been provided in the report for the period from 2017 to 2030, along with their CAGRs for the period from 2022 to 2030
• The study also offers a list of recommendations, highlights, and useful insights of the global market, which would help new companies willing to enter the market and the existing companies gain higher market share. It would also help them in the decision-making process.

Some of the prominent players in the Biotherapeutics Cell Line Development Market include:

• Merck KGaA
• Becton
• Dickinson and Company (BD)
• Danaher Corporation
• Boehringer Ingelheim Group
• Thermo Fisher Scientific, Inc
• Lonza Group Ltd.
• Probiogen AG
• Solentim Ltd.
• Selexis SA
• Sysmex Corporation.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Biotherapeutics Cell Line Development market

Process

Transfection & Selection

Single Cell Cloning

• Manual LDC
• FACs
• ClonePix
• Others

CLD Option

·       In-house

·       Outsource

·       Do-It-Yourself

·       Hybrid

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Biotherapeutics Cell Line Development industry analysis from 2022 to 2030 to identify the prevailing Biotherapeutics Cell Line Development industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Biotherapeutics Cell Line Development industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positionin facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Biotherapeutics Cell Line Development industry trends, key players, market segments, application areas, and market growth strategies.